SEC Filing Analysis: Revolution Medicines, Inc. (RVMD)

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer at Revolution Medicines has filed a notice to sell approximately $367k worth of common stock under a pre-established 10b5-1 trading plan.
• Market Impact: The transaction is of very low materiality and is not expected to have any meaningful impact on the stock price or trading volume.

Company Information

Field	Value
Company	Revolution Medicines, Inc.
Ticker Symbol	RVMD
CIK	0001628171
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Horn Margaret A
CIK	0001294192
Title/Position	Officer
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-12-15 (Approximate)
Transaction Code	Not Applicable (Proposed Sale)
Security Type	Common Stock
Shares Involved	4,711
Price Per Share	$77.81 (Approximate)
Total Value	$366,562.91
Shares Owned After	Not specified
Ownership Type	Not specified

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$366,562.91
% of Market Cap	0.0028%
Shares Transacted	4,711
% of Shares Outstanding	0.0024%
Post-Transaction Ownership	Not specified
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a large-cap company with a market capitalization of $13.10 billion, this transaction of ~$367k is financially insignificant.
• Ownership Concentration: The number of shares being sold is a negligible fraction (0.0024%) of the 193.3 million shares outstanding, indicating no change in the overall ownership structure.
• Transaction Significance: The sale represents a tiny fraction of both the company's market value and its total shares. Such small, pre-planned sales by officers are routine and typically related to personal financial management, such as tax obligations or portfolio diversification.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The sale is extremely small relative to the company's market cap and daily trading volume. Furthermore, it is being conducted under a 10b5-1 plan adopted in May 2023, which signals that the decision to sell was made well in advance and is not based on recent non-public information.

Volume & Sentiment

• Expected Volume Impact: Negligible. The number of shares is unlikely to be noticeable against the stock's average daily trading volume.
• Sentiment Indicator: Neutral. The market generally disregards small, pre-planned sales from non-CEO/CFO insiders as they are not indicative of a change in the company's outlook.

Additional Context

Transaction Notes

• Special Circumstances: The filing explicitly notes the sale is pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023. This removes any speculation about the sale's timing.
• Source of Shares: The shares to be sold were acquired through the vesting of Restricted Stock Units (RSUs) granted as compensation in prior years.